EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
Introduction
The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and osimertinib, are recommended as the first-line therapy in advanced EGFR mutation-positive NSCLC patients [[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12]]. However, approximately 20%–30% of NSCLC patients with activated EGFR mutation show primary resistance to EGFR-TKIs [13]. One intrinsic resistance mechanism was B-cell chronic lymphocytic leukemia/lymphoma-like 11 (BIM) deletion polymorphism [14].
BIM, also called BCL2L11, is a proapoptotic protein and a member of the B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) families of proteins, binding to the pro-survival Bcl-2 family members with high affinity and directly activating proapoptotic BAX and BAK to promote cell death [[15], [16], [17]]. Several previous studies have demonstrated that BIM was a key modulator of apoptosis triggered by EGFR-TKIs [[18], [19]]. BIM deletion polymorphism, a germline alteration, was reported about 12.8% in NSCLC and was thought to be associated with intrinsic resistance to EGFR-TKIs [[20], [21], [22]]. In a study that screened 2597 healthy individuals, BIM deletion polymorphism was present in 12.3% of East Asians but absent in Africans and Europeans [14]. EGFR-mutant NSCLC cells with the BIM deletion polymorphism showed impaired generation of BIM with the proapoptotic BH3 domain, as well as resistance to EGFR-TKIs induced apoptosis [[14], [15], [23]]. JY Ma et al. reported that BIM deletion polymorphism was significantly associated with a poor response to EGFR-TKIs therapy in EGFR mutation positive NSCLC patients [24]. Another study also demonstrated that decreased BIM expression level inhibited the apoptotic response and tumor shrinkage induced by EGFR-TKIs therapy [22].
Our previous study found the correlation between BIM deletion polymorphism and poor response to EGFR-TKIs in patients with activating EGFR mutations [20]. Therefore, to find out a better clinical treatment strategy, we retrospectively compared EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy as the first-line treatment for NSCLC patients harboring both activating EGFR mutations and BIM deletion polymorphism.
Section snippets
Patients
This retrospective, non-randomized analysis had screened all NSCLC patients treated in Shanghai Pulmonary Hospital from June 2014 to September 2016, and only those harboring both mutated EGFR and BIM deletion polymorphism and their therapies were either oral EGFR-TKIs alone or oral EGFR-TKIs plus intravenous chemotherapy with cisplatin or carboplatin plus pemetrexed, docetaxel, paclitaxel or gemcitabine were enrolled. All involved patients met the following inclusion criteria: they were aged
Patient characteristics
In this retrospective study, 547 NSCLC patients were screened and 69 (12.7%) harbored both EGFR mutations and BIM deletion polymorphism. Among this filtered population, one abandoned therapy, two lost connections and the other one accepted EGFR-TKI combined with bevacizumab. 65 patients were finally enrolled into this study, 36 of them received EGFR-TKIs (20 of them received gefitinib and 16 received erlotinib), among those patients, 26(72.2%) received second-line chemotherapy after disease
Discussion
The current study, to the best of our knowledge, was the first one to compare the clinical efficiency of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in the treatment of NSCLC patients with EGFR mutation and BIM deletion polymorphism. As we all know, EGFR-TKIs has undisputedly been recommended as the standard first-line therapy for NSCLC patients with activated EGFR mutation. However, several studies found that EGFR activated-mutation patients with BIM deletion polymorphism showed a poor
Conclusions
In conclusion, combination of EGFR-TKIs with chemotherapy showed a better efficacy and acceptable side effects comparing with EGFR-TKIs alone in advanced NSCLCs with activating EGFR mutation and BIM deletion polymorphism. Besides on these results, we have initiated a single arm phase II clinical trial (NCT02930954) to evaluate the effectiveness and safety of EGFR-TKIs alone versus combination of EGFR-TKIs with doublet chemotherapy or antiangiogenic drug in advanced NSCLC patients with EGFR
Funding
This study was supported in part by a grant from Shanghai Pujiang Program (17PJD036). Major disease clinical skills enhancement program of three-year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center ‘Clinical Research Plan of SHDC’ (16CR1001A). The fundamental research funds for the central universities.
Conflict of interest
None.
Acknowledgements
Sangtian Liu, Yayi He, Chao Zhao, Shengxiang Ren, Xuefei Li, Jiang Tao, Jie Zhang, Chunxia Su, Xiaoxia Chen, Weijing Cai, Guanghui Gao, Wei Li, Fengying Wu, Jiayu Li, Jing Zhao, Fei Zhou, Qiong Hu, Mingchuan Zhao collected the relevant data; Sangtian Liu, Yayi He drafted the manuscript text; Caicun Zhou and Fred R Hirsch give critical comments and revised the paper; all authors approved the final version of the manuscript.
References (43)
- et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Lancet Oncol.
(2011) - et al.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Lancet Oncol.
(2010) - et al.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Lancet Oncol.
(2012) - et al.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Lancet Oncol.
(2016) - et al.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Lancet Oncol.
(2014) - et al.
Apoptosis in targeted therapy responses: the role of BIM
Adv. Pharmacol.
(2012) - et al.
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
Mol. Cell
(2005) - et al.
Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation
J. Thorac. Oncol.
(2014) - et al.
Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients
Lung Cancer
(2013) - et al.
Clinical significance of BIM deletion polymorphism in non–small-cell lung cancer with epidermal growth factor receptor mutation
J. Thorac. Oncol.
(2014)
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Lancet Oncol.
Randomized Phase ii study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
Ann. Oncol.
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
J. Thorac. Oncol.
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
Eur. J. Cancer
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
Lung Cancer
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
J. Clin. Oncol.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
N. Engl. J. Med.
Non-small cell lung cancer, Version 5.2017, NCCN clinical practice guidelines in oncology
J. Natl. Compr. Cancer Netw.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
J. Clin. Oncol.
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
Yearb. Pulm. Dis.
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
N. Engl. J. Med.
Cited by (12)
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
2021, Lung CancerCitation Excerpt :The pro-apoptotic role of BIM relies on the pro-apoptotic domain, namely, BCL-2 homology domain 3 (BH3) [8]. However, BIM deletion polymorphism (BIM-del) specifically occurring in 12–18 % of East Asians could result in the absence of BH3, thereby blocking apoptosis [8–10]. Previous studies have reported that BIM-del is associated with resistance to first-generation EGFR-TKIs and ALK/ROS1-TKIs, and is a poor prognostic factor for NSCLC patients with EGFR/ALK/ROS1 mutations [8,9,11].
Co-delivery of erlotinib and doxorubicin by MoS<inf>2</inf> nanosheets for synergetic photothermal chemotherapy of cancer
2020, Chemical Engineering JournalCitation Excerpt :Unfortunately, acquired resistance to EGFR-TKIs has been shown in patients with NSCLC after receiving EGFR-TKIs for one year, and this resistance is mainly due to a secondary mutation in exon 20 causing methionine to replace threonine at position 790 in the kinase domain, critically attenuating the therapeutic effect of EGFR-TKIs for NSCLC [6–8]. Previous studies manifested that a combination of EGFR-TKIs and chemotherapeutic agents, especially in a time-staggered administration manner, could achieve a synergistic effect on cell proliferation in vitro [9–12]. For example, Lee et al. reported that pretreatment of lung cancer cells withEGFR-TKI Er markedly synergized the apoptotic response of lung cancer cells to the DNA-damaging agent DOX [9].
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
2023, Cancer Research and TreatmentResistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
2022, Current Opinion in Oncology
- 1
Sangtian Liu and Yayi He contributed equally to the article.